Efforts by Manufacturers Will Accelerate Bioreactors Market Growth

The global bioreactors market is expecte d to reach US$ 4,453.1 Mn in 2025 from US$ 2,760.5 Mn in 2017. The market is estimated to grow with a CAGR of 6.5% from 2018-2025. The report highlights the trends prevalent in the global bioreactors market and the factors driving the market along with those that act as restraints to its growth. The global bioreactors market is witnessing a sheer rise in the current scenario and is expected to expand in the coming years. Various technological advancements made by the players operating in the market is one of the major factor expected to propel the demand of bioreactors market. However, stringent regulatory framework in the market is expected to hinder the market growth.

Advancement in the field of bioreactors and biotechnology has enhanced the market. Many industry players have come up with innovative types of bioreactors in last few years. The advancement in the bioreactors has led to the faster and easier production of the bio products, and reduced the cost of production. In addition, the investments from public and private investors are rising for the bioreactors. The rise in the investment are enabling technological developments and standard biological parts. For instance, in April 2018, Sartorius Stedim Biotech launched the advanced mini bioreactor vessel for ambr 250 high throughput (ht) system. The new bioreactor is developed for the growth of adherent cells on micro carriers that will enable rapid, scalable cell culture process development of vaccines. The launch enhanced the portfolio of the company in biotechnology market. Moreover, in July 2017, Pall Corporation (subsidiary of Danaher) launched the mPath bioreactor control system to the biopharmaceutical market. The mPath benchtop bioreactor control system delivers accurate measurement and control of single-use process development-scale bioprocesses.

Advancement in bioreactors has added various solution for most of the industries such as, pharmaceutical, petrochemical, food and agriculture among others. These technological advancement are likely to grow the market in near future. Thus, technological advancements are expected to bring about innovative methods in the market thereby driving the global bioreactors market growth over the forecast years.

Regulatory authorities such as Food & Drug Administration, European Medicine Agency (EMA) and others has consistently shown a tough stance towards pharmaceutical can biotechnology manufacturers. Till date, the FDA’s CBER regulations do not mention anything about single?use bioreactors. Any deviations from the registered protocols, demands and requirements of these guidance leads to termination of the clinical trials undertaken by the manufacturers or outsourced organization. Moreover, the recalls for marketed products due to instances recorded for deficit of the promises in the function and performance of the product or therapeutic may tarnish the company’s reputation risking its future growth. The stringent regulations enforced by healthcare governing bodies for the bioreactors is expected to decrease the demand of bioreactors market not only in the pharmaceutical sectors but also in the medical device manufacturing capabilities. Moreover, the lack of regulatory framework in the emerging markets such as India manufacturing process is further expected to hinder the growth of the market.

Some of the prominent players operating in bioreactors market are Thermo Fisher Scientific Inc., Applikon Biotechnology BV, Merck KGaA, Sartorius AG, Eppendorf, General Electric, Bioengineering AG, Solaris Biotechnology Srl, Danaher (Pall Corporation), and Praj Industries.